AMR Monitoring to Improve Child’s Health and Mortality
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
PROJECT SUMMARY/ABSTRACT Randomized controlled trials have shown that biannual azithromycin mass drug administration (MDA) to children aged 1-59 months reduces mortality. These findings have led several high-mortality West African countries to initiate azithromycin MDA. Wider implementation, however, depends on balancing mortality benefits against antimicrobial resistance (AMR), including uncertainties about long-term selection pressure, the potential of resistant strains to cause disease, and the reversibility of AMR. The Gates Foundation-funded AVENIR II study is a large, cluster-randomized adaptive platform trial in Niger with re-randomization every 2 years. All eligible primary health center catchment areas (Centre de Santé Intégrés, CSIs) will provide biannual oral azithromycin to children aged 1-59 months. Some CSIs delay MDA in years 0-2 (then initiate it), while others stop MDA in years 2-4. This yields two trials: effectiveness (azithromycin MDA vs delayed in years 0-2) and stopping (continue vs stop in years 2-4). Nasopharyngeal and rectal samples will be collected from healthy children in the community and sick children in the clinic. Given that all samples will be biobanked at the Proctor Foundation in the United States, this presents a unique opportunity to study key questions beyond the scope of the main trial. Leveraging this large biorepository, we will 1) quantify antibiotic effectiveness once resistance has emerged and assess whether azithromycin MDA selects for AMR in colonizing and pathogenic organisms in the nasopharynx and the gut, and 2) evaluate whether resistance declines after MDA cessation and determine the fitness costs of resistant pathogens. This study will integrate culture-based approaches, susceptibility testing, short-read metagenomic sequencing, long-read whole genome sequencing, and clinical outcomes. The large sample size will provide robust individual- and population-level quantification of AMR selection, disappearance, and fitness dynamics of resistant strains. The results will inform azithromycin MDA programs and antibiotic-use guidelines.
Grant Summary
AMR Monitoring to Improve Child’s Health and Mortality is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $597K for university, nonprofit, healthcare org. Applications are due 2031-06-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $597K
2031-06-30
- 1Confirm your organization is eligible for AMR Monitoring to Improve Child’s Health and Mortality from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
AMR Monitoring to Improve Child’s Health and Mortality: Frequently Asked Questions
Who is eligible for the AMR Monitoring to Improve Child’s Health and Mortality?
AMR Monitoring to Improve Child’s Health and Mortality is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the AMR Monitoring to Improve Child’s Health and Mortality provide?
AMR Monitoring to Improve Child’s Health and Mortality provides up to $597K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the AMR Monitoring to Improve Child’s Health and Mortality deadline?
Applications for AMR Monitoring to Improve Child’s Health and Mortality are due 2031-06-30 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the AMR Monitoring to Improve Child’s Health and Mortality?
To apply for AMR Monitoring to Improve Child’s Health and Mortality, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.